Gu SY - Search Results

1

Incarvine C suppresses proliferation and vasculogenic mimicry of hepatocellular carcinoma cells via targeting ROCK inhibition.

Zhang JG, Zhang DD, Wu X, Wang YZ, Gu SY, Zhu GH, Li XY, Li Q, Liu GL. Zhang JG, et al. Among authors: gu sy. BMC Cancer. 2015 Oct 28;15:814. doi: 10.1186/s12885-015-1809-5. BMC Cancer. 2015. PMID: 26510899 Free PMC article.

2

A sensitive liquid chromatography-tandem mass spectrometry method for pharmacokinetics and tissue distribution of nuciferine in rats.

Gu S, Zhu G, Wang Y, Li Q, Wu X, Zhang J, Liu G, Li X. Gu S, et al. J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Jun 15;961:20-8. doi: 10.1016/j.jchromb.2014.04.038. Epub 2014 May 5. J Chromatogr B Analyt Technol Biomed Life Sci. 2014. PMID: 24854711

3

ROCK is involved in vasculogenic mimicry formation in hepatocellular carcinoma cell line.

Zhang JG, Li XY, Wang YZ, Zhang QD, Gu SY, Wu X, Zhu GH, Li Q, Liu GL. Zhang JG, et al. Among authors: gu sy. PLoS One. 2014 Sep 19;9(9):e107661. doi: 10.1371/journal.pone.0107661. eCollection 2014. PLoS One. 2014. PMID: 25238232 Free PMC article.

4

Nuciferine downregulates Per-Arnt-Sim kinase expression during its alleviation of lipogenesis and inflammation on oleic acid-induced hepatic steatosis in HepG2 cells.

Zhang DD, Zhang JG, Wu X, Liu Y, Gu SY, Zhu GH, Wang YZ, Liu GL, Li XY. Zhang DD, et al. Among authors: gu sy. Front Pharmacol. 2015 Oct 21;6:238. doi: 10.3389/fphar.2015.00238. eCollection 2015. Front Pharmacol. 2015. PMID: 26539118 Free PMC article.

5

Aptamer-functionalized peptide H3CR5C as a novel nanovehicle for codelivery of fasudil and miRNA-195 targeting hepatocellular carcinoma.

Liu Y, Wu X, Gao Y, Zhang J, Zhang D, Gu S, Zhu G, Liu G, Li X. Liu Y, et al. Int J Nanomedicine. 2016 Aug 12;11:3891-905. doi: 10.2147/IJN.S108128. eCollection 2016. Int J Nanomedicine. 2016. PMID: 27574422 Free PMC article.

6

PLGA nanoparticles for the oral delivery of nuciferine: preparation, physicochemical characterization and in vitro/in vivo studies.

Liu Y, Wu X, Mi Y, Zhang B, Gu S, Liu G, Li X. Liu Y, et al. Drug Deliv. 2017 Nov;24(1):443-451. doi: 10.1080/10717544.2016.1261381. Drug Deliv. 2017. PMID: 28165858 Free PMC article.

7

Cost-Utility Analysis of Once-Weekly Semaglutide, Dulaglutide, and Exenatide for Type 2 Diabetes Patients Receiving Metformin-Based Background Therapy in China.

Hu S, Wang S, Qi C, Gu S, Shi C, Mao L, Fan G. Hu S, et al. Front Pharmacol. 2022 Feb 18;13:831364. doi: 10.3389/fphar.2022.831364. eCollection 2022. Front Pharmacol. 2022. PMID: 35250578 Free PMC article.

8

Robust Prediction of Prognosis and Immunotherapy Response for Bladder Cancer through Machine Learning Algorithm.

Hu S, Gu S, Wang S, Qi C, Shi C, Qian F, Fan G. Hu S, et al. Genes (Basel). 2022 Jun 16;13(6):1073. doi: 10.3390/genes13061073. Genes (Basel). 2022. PMID: 35741835 Free PMC article.

9

Cost-utility analysis of semaglutide for type 2 diabetes after its addition to the National Medical Insurance System in China.

Hu S, Gu S, Qi C, Wang S, Qian F, Shi C, Fan G. Hu S, et al. Diabetes Obes Metab. 2023 Feb;25(2):387-397. doi: 10.1111/dom.14881. Epub 2022 Oct 23. Diabetes Obes Metab. 2023. PMID: 36193880

10

Cost-utility analysis and drug pricing of once-weekly insulin icodec versus once-daily insulin degludec for type 2 diabetes patients treated with basal insulin in China.

Hu S, Wang S, Gu S, Qi C, Shi C, Fan G. Hu S, et al. Diabetes Obes Metab. 2024 Dec;26(12):5995-6006. doi: 10.1111/dom.15973. Epub 2024 Sep 30. Diabetes Obes Metab. 2024. PMID: 39344844

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

141 results

Search Page

Filters